Sector
PharmaceuticalsOpen
₹64.02Prev. Close
₹66.89Turnover(Lac.)
₹0.41Day's High
₹64.02Day's Low
₹64.0252 Week's High
₹129.952 Week's Low
₹20.43Book Value
₹13.16Face Value
₹10Mkt Cap (₹ Cr.)
280.33P/E
15.74EPS
4.25Divi. Yield
0.3729 May 2024
12:00 AM
Dividend
Dividend Amount: 1
17 Sep 2024
12:00 AM
BookCloser
23 Sep 2024
12:00 AM
Board Meeting
Agenda : Audited Result
30 Jul 2024
12:00 AM
EGM
15 Sep 2024
12:00 AM
AGM
Announcement Date: 15 Sep, 2024
8 Apr 2024
12:00 AM
Bonus
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 10.95 | 3.91 | 1.57 | 1.57 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 46.69 | 21.38 | 14.78 | 14.03 |
Net Worth | 57.64 | 25.29 | 16.35 | 15.6 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 11.84 | 5.65 | 5.34 | 5.13 |
yoy growth (%) | 109.3 | 5.9 | 4.02 | 6.46 |
Raw materials | -3 | -0.99 | -0.95 | -1.04 |
As % of sales | 25.33 | 17.5 | 17.79 | 20.29 |
Employee costs | -4.4 | -1.96 | -1.27 | -1.09 |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 0.06 | 0.72 | 0.94 | 1.05 |
Depreciation | -1.47 | -0.96 | -0.73 | -0.46 |
Tax paid | -0.13 | -0.26 | -0.42 | -0.55 |
Working capital | 0.39 | 1.47 | 0.26 | 0.19 |
Other operating items |
| Y/e 31 Mar | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 109.3 | 5.9 | 4.02 | 6.46 |
Op profit growth | -6.61 | 2.11 | 10.28 | 24.06 |
EBIT growth | -90.08 | -26.76 | -6.95 | 15.17 |
Net profit growth | -92.29 | -12.12 | 4.55 | 321.93 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,886.65 | 162.64 | 4,52,670.53 | 237.82 | 0.72 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,820.35 | 93.02 | 1,54,512 | 430 | 0.51 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,511.2 | 30.73 | 1,22,039.52 | 1,055.94 | 0.86 | 3,752.25 | 346.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,336.75 | 75.14 | 1,12,925.71 | 469 | 0.84 | 2,394 | 201.77 |
Dr Reddys Laboratories Ltd DRREDDY | 6,660.25 | 26.98 | 1,11,144.22 | 1,417.2 | 0.6 | 5,823.9 | 1,458.55 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Dakshesh Shah
Executive Director
Payal Mehta
Independent Director
Bhoomiben Patel
Independent Director
Sarjeevan Singh
Independent Director
Sonal Deepalbhai Gandhi
Executive Director
Sanskruti Patel
Executive Director
Dhruvin Shah
Independent Director
Pinki Nirmal Sagar
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Shukra Pharmaceuticals Ltd
Summary
Shukra Pharmaceuticals Ltd (Formerly known Relish Pharmaceuticals Limited) was established in March 1993 and later on the name of Company got changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on 22 September, 2016. The Company is presently engaged in the business of manufacturing of pharmaceuticals Products and laboratory testing. The company provides varieties of products to the clientele. Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.The company has four manufacturing divisions namely tablets (General and Beta Lactum) Capsules (General and Beta Lactum), Liquid and small volume parental. Their manufacturing unit is located at Rakanpur in Gujarat.The company customers include leading Manufacturers like Cadila Healthcare Limited (Zydus), Intas Pharmaceuticals Limited, Cadila Pharmaceuticals Limited, Makers Laboratories Limited, Agenta Pharma Limited etc.The company has assisted in the development and manufacture of a wide variety of drugs and dosage forms and potency variations for many prestigious pharmaceuticals com
Read More
What is the Shukra Pharmaceuticals Ltd share price today?
The Shukra Pharmaceuticals Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹64.02 today.
What is the Market Cap of Shukra Pharmaceuticals Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Shukra Pharmaceuticals Ltd is ₹280.33 Cr. as of 23 Oct ‘24
What is the PE and PB ratio of Shukra Pharmaceuticals Ltd?
The PE and PB ratios of Shukra Pharmaceuticals Ltd is 15.74 and 5.08 as of 23 Oct ‘24
What is the 52 Week High and Low of Shukra Pharmaceuticals Ltd?
The 52-week high/low is the highest and lowest price at which a Shukra Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Shukra Pharmaceuticals Ltd is ₹20.43 and ₹129.9 as of 23 Oct ‘24
What is the CAGR of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd's CAGR for 5 Years at 91.90%, 3 Years at 187.32%, 1 Year at 196.10%, 6 Month at -22.58%, 3 Month at -19.02% and 1 Month at 5.14%.
What is the shareholding pattern of Shukra Pharmaceuticals Ltd?
The shareholding pattern of Shukra Pharmaceuticals Ltd is as follows:
Promoters - 50.96 %
Institutions - 0.11 %
Public - 48.93 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
